Mission Wealth Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $468K | Buy |
8,483
+695
| +9% | +$37.7K | 0.01% | 512 |
|
|
2025
Q4 | $382K | Sell |
7,788
-1,003
| -11% | -$46.8K | 0.01% | 553 |
|
|
2025
Q3 | $379K | Buy |
8,791
+655
| +8% | +$25.6K | 0.01% | 546 |
|
|
2025
Q2 | $312K | Sell |
8,136
-389
| -5% | -$14.9K | 0.01% | 572 |
|
|
2025
Q1 | $330K | Sell |
8,525
-1,993
| -19% | -$73K | 0.01% | 541 |
|
|
2024
Q4 | $356K | Buy |
10,518
+1,555
| +17% | +$56K | 0.01% | 515 |
|
|
2024
Q3 | $366K | Buy |
8,963
+682
| +8% | +$27.9K | 0.01% | 502 |
|
|
2024
Q2 | $319K | Buy |
8,281
+1,926
| +30% | +$81K | 0.01% | 519 |
|
|
2024
Q1 | $272K | Buy |
+6,355
| New | +$262K | 0.01% | 575 |
|
|
2023
Q3 | – | Sell |
-6,026
| Closed | -$215K | – | 560 |
|
|
2023
Q2 | $215K | Sell |
6,026
-366
| -6% | -$13.1K | 0.01% | 505 |
|
|
2023
Q1 | $227K | Sell |
6,392
-297
| -4% | -$10.4K | 0.01% | 481 |
|
|
2022
Q4 | $235K | Sell |
6,689
-109
| -2% | -$3.63K | 0.01% | 460 |
|
|
2022
Q3 | $200K | Sell |
6,798
-1,056
| -13% | -$40K | 0.01% | 469 |
|
|
2022
Q2 | $427K | Buy |
7,854
+1,968
| +33% | +$109K | 0.02% | 328 |
|
|
2022
Q1 | $320K | Sell |
5,886
-512
| -8% | -$27.8K | 0.01% | 403 |
|
|
2021
Q4 | $353K | Buy |
6,398
+1,236
| +24% | +$64.3K | 0.02% | 392 |
|
|
2021
Q3 | $247K | Sell |
5,162
-855
| -14% | -$42.9K | 0.01% | 455 |
|
|
2021
Q2 | $299K | Sell |
6,017
-429
| -7% | -$20.6K | 0.02% | 394 |
|
|
2021
Q1 | $288K | Buy |
6,446
+1,626
| +34% | +$73.8K | 0.02% | 372 |
|
|
2020
Q4 | $222K | Sell |
4,820
-6,933
| -59% | -$318K | 0.01% | 390 |
|
|
2020
Q3 | $553K | Buy |
11,753
+3,891
| +49% | +$195K | 0.04% | 189 |
|
|
2020
Q2 | $401K | Buy |
+7,862
| New | +$403K | 0.03% | 207 |
|
|
2017
Q4 | – | Sell |
-3,989
| Closed | -$202K | – | 235 |
|
|
2017
Q3 | $202K | Sell |
3,989
-760
| -16% | -$38.6K | 0.04% | 191 |
|
|
2017
Q2 | $256K | Sell |
4,749
-80
| -2% | -$4.26K | 0.05% | 152 |
|
|
2017
Q1 | $254K | Sell |
4,829
-632
| -12% | -$32.1K | 0.05% | 148 |
|
|
2016
Q4 | $263K | Buy |
5,461
+32
| +0.6% | +$1.58K | 0.05% | 141 |
|
|
2016
Q3 | $293K | Buy |
5,429
+671
| +14% | +$36.8K | 0.07% | 121 |
|
|
2016
Q2 | $258K | Sell |
4,758
-368
| -7% | -$19.4K | 0.07% | 124 |
|
|
2016
Q1 | $260K | Buy |
5,126
+502
| +11% | +$25K | 0.07% | 115 |
|
|
2015
Q4 | $233K | Buy |
4,624
+138
| +3% | +$7.03K | 0.07% | 119 |
|
|
2015
Q3 | $216K | Buy |
+4,486
| New | +$234K | 0.07% | 122 |
|
Other funds holding GSK
JEST
Mission Wealth Management's GSK Position: Q1 2026 in Review
Mission Wealth Management increased its GSK (GSK) stake by 8.9% in Q1 2026, buying an estimated $37.7K and bringing the position to 8,483 shares worth $468K. The position accounts for 0.01% of the portfolio, ranked #512.
Mission Wealth Management first reported a position in GSK in Q3 2015 and has held it in 31 quarters since. The position peaked at $553K in Q3 2020. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Mission Wealth Management held 8,483 shares of GSK worth $468K as of Q1 2026.
- Mission Wealth Management bought 695 GSK shares in Q1 2026, an estimated $37.7K.
- GSK made up 0.01% of Mission Wealth Management's portfolio in Q1 2026, its #512 holding.
- Mission Wealth Management first reported a position in GSK in Q3 2015 and has held it in 31 quarters since.
- Mission Wealth Management's GSK position peaked at $553K in Q3 2020.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Mission Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.